Sacituzumab Govitecan (SG)

DRUG13 trials

Sponsors

Dana-Farber Cancer Institute, University Hospital Heidelberg, University of California, Irvine, Gilead Sciences, Marengo Therapeutics, Inc.

Conditions

Advanced Breast CancerAdvanced HR+/HER2- Breast CancerAdvanced Triple Negative Breast CancerAdvanced Triple-Negative Breast CancerBladder CancerBrain Metastases From Breast CancerBreast CancerBreast Cancer Metastatic

Phase 1

Sacituzumab Govitecan Plus EV in Metastatic UC

RecruitingNCT04724018

Dana-Farber Cancer InstituteBladder Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter +1

Start: 2021-05-20End: 2028-05-01Target: 106Updated: 2025-11-04

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

RecruitingNCT06827613

Marengo Therapeutics, Inc.HR+, HER2-, Advanced Breast Cancer, Triple Negative Locally Advanced Non-resectable Breast Cancer

Start: 2025-03-24End: 2028-01-31Target: 50Updated: 2025-09-24

Saci Nivo Rela for TNBC

RecruitingNCT06963905

Yale UniversityMetastatic Triple-negative Breast Cancer

Start: 2025-12-29End: 2030-12-01Target: 60Updated: 2026-02-17

Phase 2

Sacituzumab Govitecan in Metastatic Colorectal Cancer

RecruitingNCT06243393

University Hospital HeidelbergMetastatic Colorectal Cancer

Start: 2024-04-19End: 2029-02-01Target: 80Updated: 2024-07-10

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

RecruitingNCT06682728

University of California, IrvineMuscle-invasive Bladder Cancer, Urothelial Carcinoma

Start: 2024-11-15End: 2026-12-01Target: 23Updated: 2025-03-26

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not yet recruitingNCT07040644

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTriple Negative Breast Neoplasms

Start: 2025-09-30End: 2028-06-30Target: 150Updated: 2025-09-08

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Not yet recruitingNCT07134556

MedSIRPDL-1 Positive, Triple Negative Breast Cancer

Start: 2026-03-01End: 2028-12-28Target: 25Updated: 2026-01-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Not yet recruitingNCT07299409

Nathalie LevasseurAdvanced Triple Negative Breast Cancer, Breast Cancer, Breast Cancer Metastatic

Start: 2025-12-31End: 2028-03-31Target: 24Updated: 2025-12-23

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Enrolling by invitationNCT07359404

YING FANAdvanced Breast Cancer

Start: 2024-04-01End: 2026-12-31Target: 60Updated: 2026-01-22

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

Not yet recruitingNCT07367178

MedSIRAdvanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer, Breast Cancer

Start: 2026-07-01End: 2028-01-01Target: 30Updated: 2026-01-28

Phase 3

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

RecruitingNCT06801834

Gilead SciencesExtensive Stage Small Cell Lung Cancer (ES-SCLC)

Start: 2025-04-04End: 2029-10-01Target: 695Updated: 2026-03-19

Unknown Phase

Trop-2 Targeted PET Probes in Advanced TNBC

RecruitingNCT07046455

Peking University Cancer Hospital & InstituteTNBC - Triple-Negative Breast Cancer

Start: 2025-03-01End: 2027-09-01Target: 20Updated: 2025-07-01

Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study

RecruitingNCT07251868

Peking University Cancer Hospital & InstituteBrain Metastases From Breast Cancer, Breast Cancer, Trop2

Start: 2024-08-01End: 2027-12-31Target: 100Updated: 2025-11-26

Related Papers

PS5-09-16: A phase 1b/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+/HER2- MBC (START-002 trial)

Clinical Cancer Research2026-02-17

Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.

Journal of Clinical Oncology2025-05-28

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).

Journal of Clinical Oncology2024-06-014 citations

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

2023-10-2162 citations

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Journal of Clinical Oncology2022-02-167 citations